Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Abstract Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ganesh Jevalikar, Ambrish Mithal, Anshu Singh, Rutuja Sharma, Khalid J. Farooqui, Shama Mahendru, Arun Dewan, Sandeep Budhiraja
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/1476d0fbc9b54c9c9febad184eeb46a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1476d0fbc9b54c9c9febad184eeb46a1
record_format	dspace
spelling	oai:doaj.org-article:1476d0fbc9b54c9c9febad184eeb46a12021-12-02T11:39:20ZLack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-1910.1038/s41598-021-85809-y2045-2322https://doaj.org/article/1476d0fbc9b54c9c9febad184eeb46a12021-03-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-85809-yhttps://doaj.org/toc/2045-2322Abstract Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.Ganesh JevalikarAmbrish MithalAnshu SinghRutuja SharmaKhalid J. FarooquiShama MahendruArun DewanSandeep BudhirajaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ganesh Jevalikar Ambrish Mithal Anshu Singh Rutuja Sharma Khalid J. Farooqui Shama Mahendru Arun Dewan Sandeep Budhiraja Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
description	Abstract Vitamin D deficiency (VDD) owing to its immunomodulatory effects is believed to influence outcomes in COVID-19. We conducted a prospective, observational study of patients, hospitalized with COVID-19. Serum 25-OHD level < 20 ng/mL was considered VDD. Patients were classified as having mild and severe disease on basis of the WHO ordinal scale for clinical improvement (OSCI). Of the 410 patients recruited, patients with VDD (197,48.2%) were significantly younger and had lesser comorbidities. The levels of PTH were significantly higher in the VDD group (63.5 ± 54.4 vs. 47.5 ± 42.9 pg/mL). The proportion of severe cases (13.2% vs.14.6%), mortality (2% vs. 5.2%), oxygen requirement (34.5% vs.43.4%), ICU admission (14.7% vs.19.8%) was not significantly different between patients with or without VDD. There was no significant correlation between serum 25-OHD levels and inflammatory markers studied. Serum parathormone levels correlated with D-dimer (r 0.117, p- 0.019), ferritin (r 0.132, p-0.010), and LDH (r 0.124, p-0.018). Amongst VDD patients, 128(64.9%) were treated with oral cholecalciferol (median dose of 60,000 IU). The proportion of severe cases, oxygen, or ICU admission was not significantly different in the treated vs. untreated group. In conclusion, serum 25-OHD levels at admission did not correlate with inflammatory markers, clinical outcomes, or mortality in hospitalized COVID-19 patients. Treatment of VDD with cholecalciferol did not make any difference to the outcomes.
format	article
author	Ganesh Jevalikar Ambrish Mithal Anshu Singh Rutuja Sharma Khalid J. Farooqui Shama Mahendru Arun Dewan Sandeep Budhiraja
author_facet	Ganesh Jevalikar Ambrish Mithal Anshu Singh Rutuja Sharma Khalid J. Farooqui Shama Mahendru Arun Dewan Sandeep Budhiraja
author_sort	Ganesh Jevalikar
title	Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
title_short	Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
title_full	Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
title_fullStr	Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
title_full_unstemmed	Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19
title_sort	lack of association of baseline 25-hydroxyvitamin d levels with disease severity and mortality in indian patients hospitalized for covid-19
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/1476d0fbc9b54c9c9febad184eeb46a1
work_keys_str_mv	AT ganeshjevalikar lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT ambrishmithal lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT anshusingh lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT rutujasharma lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT khalidjfarooqui lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT shamamahendru lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT arundewan lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19 AT sandeepbudhiraja lackofassociationofbaseline25hydroxyvitamindlevelswithdiseaseseverityandmortalityinindianpatientshospitalizedforcovid19
_version_	1718395686322438144

Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19

Ejemplares similares